Web06. apr 2024. · Between Aug 2, 2024 and Apr 28, 2024, 84 patients were enrolled and received gumarontinib (median follow-up 13.5 months [IQR 8.7–17.1]), at data cut-off (Apr 28, 2024) five patients whose METex14 status could not be confirmed by a central laboratory were excluded from the efficacy analysis.The objective response rate was … Web21. mar 2024. · This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS …
History of Changes for Study: NCT05351346
Web11. apr 2024. · 3 Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China. 4 Department of Medical Oncology, The First Hospital of China Medical University, Liaoning, China. 5 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union … WebLiaoning Cancer Hospital & Institute. MD PhD. Contact. Connect with experts in your field. Join ResearchGate to contact this researcher and connect with your scientific … coleman inflated hot tub
Gumarontinib in patients with non-small-cell lung cancer …
Webgastric cancer Liaoning Cancer Hospital & Institute Yan Zhao, Ya-hong Luo, Tao Yu, et al. SPO.4.20 Cancer Treatment and Translational Research in China . BACKGROUND 1. Gastric cancer (GC) is a major health threats • The incidence rate of GC ranked 2nd in male and 3rd in female in WebBreast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong Province 250117, China Xinwen Zhang Center of Implant Dentistry, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Disease, … Web29. jun 2024. · HER2-positive Breast Cancer HER2-positive Biliary Tract Cancer HER2-Positive Salivary Gland Carcinomas HER2-Positive Advanced Solid Tumor: Drug: GQ1001: Phase 1: Study Design. ... GeneQuantum Healthcare (Suzhou) Co., Ltd. ClinicalTrials.gov Identifier: NCT04450732 Other Study ID Numbers: GQ1001X2101 : coleman inflatable hot tubs and spas